Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
positive tags : Therapeutics save search
Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CERE | $42.15 0.02% 0.02% 810K
|
Finance
|
| O: 0.78%
H: 0.0%
C: 0.0%
disease positive for topline parkinson’s trial therapeutics results living
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Published: 2024-04-15 (Crawled : 12:00) - globenewswire.com
VIRX | $0.88 -3.19% -3.3% 53K
|
Manufacturing
|
| O: -12.71%
H: 0.97%
C: -24.27%
t-cell positive topline trial therapeutics results
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
Published: 2024-04-11 (Crawled : 11:00) - globenewswire.com
IPSC | $3.06 2.86% 2.78% 110K
|
Professional, Scientific, and T...
|
| O: 3.39%
H: 11.53%
C: 2.02%
disease million pipeline acquisition expansion therapeutics
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
QLGN | $0.301 -3.43% -3.55% 30K
|
Health Technology
|
| O: 3.2%
H: 0.0%
C: -0.28%
qn-302 association positive cancer research meeting therapeutics
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
GALT | $3.37 -0.3% -0.3% 210K
|
Health Technology
|
| O: 2.19%
H: 6.15%
C: 5.35%
metabolic positive for meeting hypertension therapeutics study
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
Published: 2024-04-05 (Crawled : 12:00) - globenewswire.com
TARA | $2.62 -4.73% -4.96% 210K
|
Health Technology
|
| O: 16.92%
H: 11.06%
C: -22.77%
tara-002 positive program therapeutics
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BIOR | $0.6156 2.69% 2.62% 100K
|
Health Care and Social Assistan...
|
| O: 1.34%
H: 0.0%
C: -4.21%
bt-600 positive trial therapeutics results platform
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $5.17 -5.31% -5.61% 520K
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers
Published: 2024-04-01 (Crawled : 19:00) - biospace.com/
CNTX | $1.39 -1.42% -1.44% 5.7K
|
Health Technology
|
| O: 8.7%
H: 3.33%
C: -8.67%
ctim-76 application therapeutics
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
ALGS | $0.735 -7.33% -7.9% 140K
|
Health Technology
|
| O: -1.96%
H: 0.0%
C: -2.1%
alg-0550 alg-000184 positive therapeutics
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
Published: 2024-03-25 (Crawled : 14:00) - biospace.com/
ATXS | $9.745 -7.54% -8.16% 1.2M
|
Manufacturing
|
| O: 10.71%
H: 0.9%
C: -11.94%
star-0215 positive trial therapeutics results
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
Published: 2024-03-22 (Crawled : 12:00) - globenewswire.com
OTLK P | $8.15 -1.69% -1.72% 270K
|
Health Technology
|
| O: 52.98%
H: 8.82%
C: -19.87%
ons-5010 therapeutics chmp positive treatment
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
Published: 2024-03-19 (Crawled : 15:30) - biospace.com/
HOTH | $1.22 3.39% 3.28% 22K
|
Health Technology
|
| O: 21.74%
H: 19.29%
C: -3.57%
disease pre-clinical positive treatment alzheimer's therapeutics ht-alz study
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
Published: 2024-03-18 (Crawled : 12:00) - globenewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.46%
H: 0.23%
C: -1.88%
vmt01 melanoma nivolumab collaboration therapeutics agreement
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
Published: 2024-03-15 (Crawled : 12:30) - globenewswire.com
FBIO | $1.765 -2.49% -2.55% 190K
|
Health Technology
|
| O: 2.98%
H: 15.03%
C: 11.85%
ATXI | $0.1295 -3.79% -3.94% 320K
|
Health Technology
|
| O: -0.26%
H: 13.2%
C: 1.88%
nasdaq positive therapeutics
Silence Therapeutics Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(a)
Published: 2024-03-13 (Crawled : 15:00) - biospace.com/
SLN | $22.75 3.32% 3.21% 310K
|
Health Technology
|
| O: -5.02%
H: 5.71%
C: 4.11%
positive ongoing topline therapeutics study
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Published: 2024-03-12 (Crawled : 12:30) - biospace.com/
RGLS | $2.13 -4.05% -4.23% 220K
|
Health Technology
|
| O: 68.84%
H: 62.66%
C: 1.29%
rgls8429 disease kidney positive treatment topline trial therapeutics
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsCompany maintains solid cash position of $158.9 million
Published: 2024-03-07 (Crawled : 15:30) - biospace.com/
RAPT | $7.96 0.38% 0.38% 790K
|
Health Technology
|
| O: 0.66%
H: 4.57%
C: 0.87%
year million therapeutics financial
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
Published: 2024-03-07 (Crawled : 14:30) - biospace.com/
APVO 4 d | $0.721 -6.36% -6.8% 230K
|
Health Technology
|
| O: 19.53%
H: 41.18%
C: -13.73%
apv-527 alg.apv-527 positive bioscience tumor therapeutics study
AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 08:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
lung drug cancer treatment application therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.